MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENTREPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

被引：0

作者：

Redondo, Andres ^{[1
,2
]}

Follana, Philippe ^{[3
,4
]}

Scambia, Giovanni ^{[5
,6
]}

Asselain, Bernard ^{[7
]}

Marme, Frederik ^{[8
,9
]}

Mirza, Mansoor ^{[10
,11
]}

Laudani, Maria Elena ^{[12
]}

Madry, Radoslaw ^{[13
,14
]}

Glasspool, Rosalind ^{[15
,16
,17
]}

You, Benoit ^{[18
,19
]}

Jesus Rubio-Perez, Maria ^{[20
,21
]}

Zamagni, Claudio ^{[22
,23
]}

El-Balat, Ahmed ^{[24
,25
]}

Hardy-Bessard, Anne Claire ^{[26
,27
]}

Oaknin, Ana ^{[28
,29
]}

Ronzino, Graziana ^{[30
,31
]}

Shaw, Bob ^{[32
]}

Nakamura, Hitomi ^{[33
]}

Berton, Dominique ^{[34
]}

Pujade-Lauraine, Eric ^{[35
]}

机构：

[1] La Paz Univ Hosp, Madrid, Spain

[2] GEICO, Dept Med, Madrid, Spain

[3] Ctr Antoine Lacassagne, Nice, France

[4] GINECO, Dept Med Oncol, Nice, France

[5] Fdn Policlin Univ A Gemelli, IRCCS, UOC Ginecol Oncol, Rome, Italy

[6] MITO, Dipartimento Salute Donna & Bambino & Salute Pubb, Rome, Italy

[7] ARCAGY GINECO, Dept Biostat, Paris, France

[8] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[9] AGO, Med Fac Mannheim, Mannheim, Germany

[10] Rigshosp, Copenhagen, Denmark

[11] NSGO, Dept Canc Treatment, Copenhagen, Denmark

[12] Univ Turin, St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy

[13] Poznan Univ Med Sci, Poznan, Poland

[14] PGOG, Dept Gynecol Oncol, Poznan, Poland

[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[17] NCRI, Med Oncol, Glasgow, Lanark, Scotland

[18] HCL Ctr Hosp Lyon Sud, Lyon, France

[19] GINECO, Dept Med Oncol, Lyon, France

[20] Reina Sofia Univ Hosp, Cordoba, Spain

[21] GEICO, Dept Med Oncol, Cordoba, Spain

[22] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[23] MITO, Med Oncol Unit, Bologna, Italy

[24] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany

[25] AGO, Dept Gynecol & Gynecol Oncol, Frankfurt, Germany

[26] Ctr CARIO HPCA, Plerin, France

[27] GINECO, Med Oncol, Plerin, France

[28] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[29] GEICO, Gynaecol Canc Programme, Barcelona, Spain

[30] Vito Fazzi Hosp, Lecce, Italy

[31] MITO, Med Oncol Unit, Lecce, Italy

[32] AstraZeneca, Stat, Cambridge, England

[33] AstraZeneca, Global Med Affairs, Cambridge, England

[34] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[35] ARCAGY GINECO, Dept Med Oncol, Paris, France

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O025/#522

引用

页码：A15 / A15

页数：1

共 50 条

[21] Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Mirza, Mansoor R.
Benigno, B.
Dorum, A.
Mahner, S.
Bessette, P.
Barcel, I. Bover
Berton-Rigaud, D.
Ledermann, J. A.
Rimel, B. J.
Herrstedt, J.
Lau, S.
du Bois, A.
Casado Herraez, A.
Kalbacher, E.
Buscema, J.
Lorusso, D.
Vergote, I
Levy, T.
Wang, P.
de Jong, F. A.
Gupta, D.
Matulonis, U. A.
GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 442 - 448
[22] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab ( bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Schnelzer, A.
Harter, P.
Sehouli, J.
Canzler, U.
Marme, F.
De Gregorio, N.
Buderath, P.
Lueck, H. J.
Gropp-Meier, M.
Runnebaum, I
Belau, A.
Renner, S.
Schmalfeldt, B.
El-Balat, A.
Burges, A.
Hillemanns, P.
Denschlag, D.
Bauerschlag, D.
Hanker, L.
Ray-Coquard, I
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E87 - E87
[23] Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev
de Gregorio, Nikolaus
Harter, Philipp
Sehouli, Lalid
Canzler, Ulrich
Marme, Frederik
Buderath, Paul
Lueck, Hans-Joachim
Gropp-Meier, Martina
Runnebaum, Ingo B.
Belau, Antje
Renner, Stefan
Schmalfeldt, Barbara
El-Balat, Ahmed
Burges, Alexander
Hillemanns, Peter
Denschlag, Dominik
Bauerschlag, Dirk
Hanker, Lars
Schnelzer, Andreas
Ray-Coquard, Isabelle
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 93 - 93
[24] Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Poveda, Andres
Floquet, Anne
Ledermann, Jonathan A.
Asher, Rebecca
Penson, Richard T.
Oza, Amit M.
Korach, Jacob
Huzarski, Tomasz
Pignata, Sandro
Friedlander, Michael
Baldoni, Alessandra
Park-Simon, Tjoung-Won
Sonke, Gabe S.
Lisyanskaya, Alla Sergeevna
Kim, Jae-Hoon
Abdo Filho, Elias
Vergote, Ignace
Rowe, Phil
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Ray-Coquard, I. L.
Pautier, P.
Pignata, S.
Perol, D.
Gonzalez-Martin, A.
Sevelda, P.
Fujiwara, K.
Vergote, I. B.
Colombo, N.
Maenpaa, J.
Selle, F.
Sehouli, J.
Lorusso, D.
Alia, E. M. Guerra
Lefeuvre-Plesse, C.
Canzler, U.
Lortholary, A.
Marme, F.
Pujade-Lauraine, E.
Harter, P.
ANNALS OF ONCOLOGY, 2019, 30 : 894 - +
[26] A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
Matulonis, Ursula
Mahner, Sven
Wenham, Robert Michael
Ledermann, Jonathan A.
Monk, Bradley J.
Campo, Jose Maria Dei
Berek, Jonathan S.
Vergote, Ignace
Fabbro, Michel
Katsaros, Dionyssios
Marth, Christian
Lorusso, Domenica
Herrstadt, Jorn
Agarwal, Shefali
Martell, Robert E.
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
Sabatier, R.
Rousseau, F.
Joly, F.
Cropet, C.
Montegut, C.
Frindte, J.
Cinieri, S.
Guerra-Alia, E. M.
Bogner, G.
Yoshida, H.
Vergote, I.
Colombo, N.
Hietanen, S.
Largillier, R.
Canzler, U.
Gratet, A.
Marme, F.
Pujade-Lauraine, E.
Favier, L.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2021, 32 : S737 - S738
[28] Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Fabbro, Michel
Moore, Kathleen N.
Dorum, Anne
Tinker, Anna, V
Mahner, Sven
Bover, Isabel
Banerjee, Susana
Tognon, Germana
Goffin, Frederic
Shapira-Frommer, Ronnie
Wenham, Robert M.
Hellman, Kristina
Provencher, Diane
Harter, Philipp
Palacio Vazquez, Isabel
Follana, Philippe
Pineda, Mario J.
Mirza, Mansoor R.
Hazard, Sebastien J.
Matulonis, Ursula A.
GYNECOLOGIC ONCOLOGY, 2019, 152 (03) : 560 - 567
[29] PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Loverix, Liselore
Vergote, Ignace
Busschaert, Pieter
Vanderstichele, Adriaan
Venken, Tom
Boeckx, Bram
Harter, Philipp
Brems, Hilde
Van Nieuwenhuysen, Els
Pignata, Sandro
Baert, Thais
Gonzalez-Martin, Antonio
Han, Sileny
Marth, Christian
Neven, Patrick
Colombo, Nicoletta
Berteloot, Patrick
Maeenpaeae, Johanna
Olbrecht, Siel
Laga, Tina
Sablon, Erwin
Ray-Coquard, Isabelle
Pujade-Lauraine, Eric
Lambrechts, Diether
Van Gorp, Toon
EUROPEAN JOURNAL OF CANCER, 2023, 188 : 131 - 139
[30] Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Fujiwara, K.
Harter, P.
Leary, A.
Perol, D.
Pignata, S.
Gonzalez-Martin, A.
Petru, E.
van Nieuwenhuysen, E.
Colombo, N.
Maenpaa, J.
Selle, F.
de Gregorio, N.
Lorusso, D.
Alia, E. M. Guerra
Lefeuvre-Plesse, C.
Buderath, P.
Lortholary, A.
Burges, A.
Pujade-Lauraine, E.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →